{"id":"NCT02665273","sponsor":"Montefiore Medical Center","briefTitle":"Greater Occipital Nerve Block With Bupivacaine for Acute Migraine","officialTitle":"A Randomized, Sham-controlled Trial of Greater Occipital Nerve Block as Second Line Therapy for ED Patients With Acute Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-01","primaryCompletion":"2018-01","completion":"2018-01","firstPosted":"2016-01-27","resultsPosted":"2020-08-11","lastUpdate":"2020-08-11"},"enrollment":28,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"PROCEDURE","name":"Greater occipital nerve block","otherNames":[]},{"type":"DRUG","name":"Bupivacaine","otherNames":[]}],"arms":[{"label":"Greater occipital nerve block","type":"EXPERIMENTAL"},{"label":"Sham","type":"SHAM_COMPARATOR"}],"summary":"This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only enrolled if they fail first line therapy with metoclopramide.","primaryOutcome":{"measure":"Number of Participants Who Achieve Freedom From Headache","timeFrame":"30 minutes","effectByArm":[{"arm":"Greater Occipital Nerve Block","deltaMin":4,"sd":null},{"arm":"Sham","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["injection site reaction","neck pain","dizziness"]}}